Plasma osteopontin concentrations in patients with cutaneous melanoma

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1575-1580

  Filia, A ^a   Elliott, F ^a   Wind, T ^a   Field, S ^a   Davies, J ^a   Kukalizch, K ^a   Randerson Moor, J ^a   Harland, M ^a   Bishop, D T ^a   Banks, R E ^a   Newton Bishop, J A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; ELISA; Melanoma; Osteopontin; Prognosis

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; UPREGULATION;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOPONTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84882616760     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2666     Document Type: Article

References (40)

1. Gogas H, Eggermont AM, Hauschild A, et al: Biomarkers in melanoma. Ann Oncol 20 (Suppl 6): vi8-v13, 2009.
2. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206, 2009.
3. Hofmann MA, Gussmann F, Fritsche A, et al: Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 19: 17-23, 2009.
4. Paschen A, Sucker A, Hill B, et al: Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15: 5208-5215, 2009.
5. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004.
6. Das R, Philip S, Mahabeleshwar GH, Bulbule A and Kundu GC: Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57: 441-447, 2005.
7. Packer L, Pavey S, Parker A, et al: Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 27: 1778-1786, 2006.
8. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006.
9. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226, 2008.
10. Smith AP, Hoek K and Becker D: Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4: 1018-1029, 2005.
11. Rangel J, Nosrati M, Torabian S, et al: Osteopontin as a molecular prognostic marker for melanoma. Cancer 112: 144-150, 2008.
12. Zhou Y, Dai DL, Martinka M, et al: Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052, 2005.
13. Maier T, Laubender RP, Sturm RA, et al: Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol 26: 1084-1091, 2012.
14. Conway C, Mitra A, Jewell R, et al: Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15: 6939-6946, 2009.
15. Jaeger J, Koczan D, Thiesen HJ, et al: Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13: 806-815, 2007.
16. Soikkeli J, Podlasz P, Yin M, et al: Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol 177: 387-403, 2010.
17. Kashani-Sabet M, Venna S, Nosrati M, et al: A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15: 6987-6992, 2009.
18. Alonso SR, Tracey L, Ortiz P, et al: A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67: 3450-3460, 2007.
19. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M and Lindmark-Mansson H: The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16: 1087-1097, 2007.
20. Li Y, Li L, Wang JT, Kan X and Lu JG: Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol 29: 1429-1434, 2012.
21. Sun J, Xu HM, Zhou HJ, et al: The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 1-7, 2010.
22. Isa S, Kawaguchi T, Teramukai S, et al: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 4: 1104-1110, 2009.
23. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28: 936-941, 2010.
24. Wheatley-Price P, Yang B, Patsios D, et al: Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 28: 3316-3322, 2010.
25. Reiniger IW, Wolf A, Welge-Lussen U, Mueller AJ, Kampik A and Schaller UC: Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 143: 705-707, 2007.
26. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R and Schaller UC: Osteopontin and melanoma inhibitory activity: comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223: 239-243, 2009.
27. Kadkol SS, Lin AY, Barak V, et al: Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47: 802-806, 2006.
28. Kluger HM, Hoyt K, Bacchiocchi A, et al: Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17: 2417-2425, 2011.
29. Newton-Bishop JA, Beswick S, Randerson-Moor J, et al: Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 27: 5439-5444, 2009.
30. Wind TC, Messenger MP, Thompson D, Selby PJ and Banks RE: Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. Ann Clin Biochem 48: 112-120, 2011.
31. Sim SH, Messenger MP, Gregory WM, et al: Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer 107: 1131-1137, 2012.
32. StataCorp: Stata Statistical Software: Release 10. College Station, TX, StataCorp LP, 2007.
33. Sennels HP, Jacobsen S, Jensen T, et al: Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest 67: 821-835, 2007.
34. Homsi J, Kashani-Sabet M, Messina JL and Daud A: Cutaneous melanoma: prognostic factors. Cancer Control 12: 223-229, 2005.
35. Slingluff CL Jr, Vollmer RT, Reintgen DS and Seigler HF: Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann Surg 208: 150-161, 1988.
36. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
37. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
38. Kulasingam V and Diamandis EP: Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 5: 588-599, 2008.
39. Utikal J, Schadendorf D and Ugurel S: Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298: 469-477, 2007.
40. Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I and Pe'er J: The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res 31: 345-349, 2011.